Review
Taranabant, a novel cannabinoid type 1 receptor inverse agonist
Affiliations
- PMID:18821475
Item in Clipboard
Review
Taranabant, a novel cannabinoid type 1 receptor inverse agonist
Bradley A Fremming et al. Curr Opin Investig Drugs.2008 Oct.
Display options
Format
Display options
Format
Abstract
Merck & Co Inc is developing the cannabinoid receptor type 1 inverse agonist taranabant for the potential treatment of obesity and nicotine dependence. By October 2006, the drug had entered phase III trials for obesity, and by May 2008, a phase II study of taranabant as an aid to smoking cessation in chronic cigarette smokers had been completed.